Daniel L Solomon, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2420 Lake Ave, Ashtabula, OH 44004 Phone: 440-997-2262 |
Ronald Casselberry, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2420 Lake Ave, Ashtabula, OH 44004 Phone: 440-997-2262 |
David J Krantz, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2420 Lake Ave, Ashtabula, OH 44004 Phone: 440-997-2262 |
Samuel S Lee, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2420 Lake Ave, Ashtabula, OH 44004 Phone: 440-997-2262 |
News Archive
Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development.
There is currently not enough evidence related to the effects of noncaloric sweeteners on appetite, short‑term intake, and risk of suffering from cancer or diabetes, as shown by a study recently published in the scientific journal 'Advances in Nutrition'.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
Chemotherapy is standard treatment for patients with advanced non-small cell lung cancer, although benefits are modest and toxicity substantial. Massimo Di Maio and colleagues hypothesised that neutropenia, a haematological toxicity, could be a predictor of drug activity and treatment efficacy.
The Committee for Medicinal Products for Human Use (CHMP) of the The European Medicines Agency (EMA) has recommended today to lift the EU-wide suspension of the marketing authorizations of both octagam® and octagam®10% which has been in place since September 2010, subject to certain conditions.
› Verified 4 days ago